| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Forma Therapeutics Holdings, Inc. | Officer | Common Stock | 134,521 | $679,331 | $5.05 | 23 Feb 2022 | Direct |
| LAVA Therapeutics NV | Director | Common Shares (Right to Buy) | 33,390 | 13 Feb 2025 | Direct | ||
| LAVA Therapeutics NV | Director | Share Options (Right to Buy) | 0 | 13 Nov 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| LVTX | LAVA Therapeutics NV | 13 Nov 2025 | 1 | $0 | 4 | Director | 17 Nov 2025, 16:30 |
| LVTX | LAVA Therapeutics NV | 13 Feb 2025 | 1 | $0 | 4 | Director | 18 Feb 2025, 20:15 |
| LVTX | LAVA Therapeutics NV | 01 Jan 2025 | 0 | $0 | 3 | Director | 02 Jan 2025, 09:34 |
| /report/000089924322007909-wadlinger-mary-e-2022-02-23 | Forma Therapeutics Holdings, Inc. | 23 Feb 2022 | 1 | -$45,798 | 4 | Officer | 25 Feb 2022, 16:01 |